Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Oxford BioMedica
Phase I/II trial results look good so far in breast cancer patients
July 30th, 2003
Oxford BioMedica (LSE:OXB) announced encouraging results from its ongoing, small, Phase I/II trial with MetXia in breast cancer patients. The company also announced regulatory progress towards starting a Phase I/II trial with MetXia in pancreatic cancer. MetXia is Oxford BioMedica's leading gene-based cancer therapeutic. The product is based on a highly engineered retrovirus gene delivery system expressing a specific human cytochrome P450 gene. MetXia converts the tumor into a 'drug factory,' enabling increased local production of the antitumor, cytotoxic derivative of the prodrug cyclophosphamide. MetXia is potentially useful in the treatment of all...
Source: Biotech Week (2003-07-30)
|
